• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume8, Issue3

ASSOCIATION BETWEEN SERUM ZINC-ALPHA-2-GLYCOPROTEIN WITH THYROID HORMONE IN NEWLY DIAGNOSED HYPERTHYROIDISM

    Ahmed Nofal Ali, Ihab Mohamed Salem, Atef Gouda Hussein, Mohamed Gaber Hamed

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4669-4678

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background: Thyroid dysfunction may contribute to lipids metabolic disorders. Zinc-alpha-2-glycoprotein (ZAG) function comes from its specific lipolytic action.  This study aimed to find the association of serum ZAG levels with thyroxin and lipid profile in patients with hyperthyroidism before and after carbimazole treatment. Patients and methods: This study was conducted as a case-cohort study done on 23 patients suffering from typical symptoms of hyperthyroidism. In addition, 23 apparently healthy individuals were chosen as a control group. All patients were selected from Internal medicine department, Zagazig University Hospitals. Results: The present study showed fasting plasma glucose levels and SBP were significantly higher among case group. The difference in lipid profile in case group before and after treatment with carbimazole.There was significant higher levels in total cholesterol and TG Levels after treatment. The difference in lipid profile in case group before and after treatment with carbimazole. There was significant reduction in HDL Levels after treatment. While LDLwas significant higher after the treatment. Significant reduction in ZAG levels after treatment with carbimazole in case group. Conclusion: ZAG has a novel role in lipid metabolism as it has specific lipolytic action so it has a potential role in body weight regulation, protect against fatty liver by ameliorating hepatic steatosis, insulin resistance and inflammation.
Keywords:
    Zinc-Alpha-2-Glycoprotein TSH Hyperthyroidism SBP LDL
  • PDF (345 K)
  • XML
(2021). ASSOCIATION BETWEEN SERUM ZINC-ALPHA-2-GLYCOPROTEIN WITH THYROID HORMONE IN NEWLY DIAGNOSED HYPERTHYROIDISM. European Journal of Molecular & Clinical Medicine, 8(3), 4669-4678.
Ahmed Nofal Ali, Ihab Mohamed Salem, Atef Gouda Hussein, Mohamed Gaber Hamed. "ASSOCIATION BETWEEN SERUM ZINC-ALPHA-2-GLYCOPROTEIN WITH THYROID HORMONE IN NEWLY DIAGNOSED HYPERTHYROIDISM". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 4669-4678.
(2021). 'ASSOCIATION BETWEEN SERUM ZINC-ALPHA-2-GLYCOPROTEIN WITH THYROID HORMONE IN NEWLY DIAGNOSED HYPERTHYROIDISM', European Journal of Molecular & Clinical Medicine, 8(3), pp. 4669-4678.
ASSOCIATION BETWEEN SERUM ZINC-ALPHA-2-GLYCOPROTEIN WITH THYROID HORMONE IN NEWLY DIAGNOSED HYPERTHYROIDISM. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 4669-4678.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 141
  • PDF Download: 156
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus